Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines

Annals of Hematology

Volumn 91, Issue 10, 2012, Pages 1613-1622

  Cosenza, Maria ^a   Civallero, Monica ^a   Grisendi, Giulia ^a   Marcheselli, Luigi ^a   Roat, Erika ^a   Bari, Alessia ^a   Sacchi, Stefano ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

AKT; Enzastaurin; Indolent B cell lymphoma; Lenalidomide; MAPK; Signaling pathways

Indexed keywords

ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3BETA; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE C;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DRUG SYNERGISM; HUMANS; INDOLES; LYMPHOMA, B-CELL; THALIDOMIDE;

EID: 84867329976     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1490-6     Document Type: Article

References (40)

1. Jaffe ES, Harris NL, Vardiman JW Stein H (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues, vol 352. IARC Press, Lyon, p 85
2. Luminari S, Cesaretti M, Rashid I, Mammi C, Montanini A, Barbolini E et al (2007) Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. Hematol Oncol 25:189-197
3. Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A et al (2003) Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKC-beta. Bioorg Med Chem Lett 13:1857-1859
4. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN et al (2005) The protein kinase C-beta selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-7469
5. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS et al (2006) The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126:1641-1647
6. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y et al (2007) Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 109:4964-4972
7. Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT et al (2007) Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 109:1669-1677
8. Morgillo F, Martinelli E, Troiani T, Laus G, Pepe S, Gridelli C et al (2008) Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C beta inhibitor, in non-small cell lung cancer cells. Mol Cancer Ther 7:1698-1707
9. Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ et al (2008) Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 68:1916-1926
10. Neri A, Marmiroli S, Tassone P, Lombardi L, Nobili L, Verdelli D et al (2008) The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 49:1374-1383
11. Civallero M, Cosenza M, Grisendi G, Marcheselli L, Todoerti K, Sacchi S (2010) Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma 51:671-679
12. Richardson PG, Schlossman RL,Weller E, Hideshima T, Mitsiades C, Davies F et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067
13. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al (2005) Efficacy of Lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557
14. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS et al (2010) Efficacy of Lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 51:85-88
15. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297
16. Sissung TM, Thordardottir S, Gardner ER, Figg WD (2009) Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer. Anticancer Agents Med Chem 9:1058-1069
17. Amato RJ, Hernandez-McClain J, Saxena S, Khan M (2008) Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 31:244-249
18. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al (2007) Lenalidomide plus Dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142
19. List A, Gordon D, Bennett J, Giagounidis A, Raza A, Feldman E et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465
20. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950
21. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322
22. Zhu D, Corral LG, Fleming YW, Stein B (2008) Immunomodulatory drugs Revlimid (Lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57:1849-1859
23. Verhelle D, Corral LG,Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K et al (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 67:746-755
24. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI (2006) Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30:849-858
25. Gartner S, Kaplan HS (1980) Long-term culture of human bone marrow cells. Proc Natl Acad Sci U S A 77:4756-4759
26. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
27. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681
28. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87:227-253
29. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF (2008) New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9:1157-1165
30. Hallek M, Eichhorst BF (2004) Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J 5:20-30
31. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP (2006) Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 98:1655-1663
32. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100:1780-1791
33. Srikanth M, Davies FE, Morgan GJ (2008) An update on drug combinations for treatment of myeloma. Expert Opin Investig Drugs 17:1-12
34. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR et al (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24:4092-4099
35. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ et al (2007) Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25:1741-1746
36. Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M et al (2008) A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 19:247-253
37. Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS et al (2007) Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 13:4474-4481
38. Ivanov V, Tabouret E, Chuto G, Chetaille B, Fezoui H, Coso D et al (2010) Rituximab-Lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large Bcell non-Hodgkin lymphoma. Leuk Lymphoma 51(9):1758-1760
39. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G et al (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 27:5404-5409
40. Fowler NH, McLaughlin P, Hagemeister FB, Kwak LW, Fanale MA, Neelapu SS, et al (2010) Complete response rates with Lenalidomide plus rituximab for untreated indolent B-cell non- Hodgkin's lymphoma. J Clin Oncol 28; Abstract 8036